Previous 10 | Next 10 |
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for VKTX on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. VKTX was trading at $52.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and ...
2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...
2024-06-18 07:50:00 ET Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping up to make a big splash in their target markets, assuming the...
2024-06-17 09:13:40 ET Summary Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a market dominated by Novo Nordisk and Eli Lilly. ...
2024-06-15 09:31:00 ET The S&P 500 remains near record levels as the markets have been strong this year. Finding good stocks to buy in such a hot market can be challenging. But a couple of growth stocks with lots of potential, based on their price targets from Wall Street, are V...
2024-06-15 07:45:00 ET A business can look to be in solid shape but still not necessarily be a great investment overall. A good example of that is Viking Therapeutics (NASDAQ: VKTX) . The company has been doing a lot of things well lately, and there's a lot of hope and optimism arou...
2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...
2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...
2024-06-10 09:45:00 ET Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite the...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-01 08:15:00 ET Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks ...
2024-06-30 06:53:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmu...